B_table indent_4.5 mm N_table indent_4 mm 維亞生物科技控股集團 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 用簡體 李 向 榮_榮 字 用簡體 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 截至二零二 四 年六月三十日止六個月之 中期業績公告 維亞生物科技控股集團（「本公司」或「公 司」，連 同 其 附 屬 公 司 統 稱「本集團」、「集 團」 或「維 亞」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 集 團 截 至 二 零 二 四 年六月三十日 止 六 個 月（「報告期」）的 未 經 審 核 簡 明 綜合財務業績。 財務概要 | --- | --- | --- | |--------------------------------------------------------------|------------ ...

香港主要營業地點 香港銅鑼灣 希慎道33號 利園一期 19樓1901室 股份過戶登記總處 Maples Fund Services (Cayman) Limited PO Box 1093, Boundary Hall Cricket Square Grand Cayman, KY1-1102 Cayman Islands 香港股份過戶登記分處 卓佳證券登記有限公司 香 港 夏愨道16號 遠東金融中心17樓 股份代號 1873 公司網址 www.vivabiotech.com 剛剛過去的二零二三年，雖然不可避免地受到美元加息及流動性收緊的影響，全球生物醫藥 行業投融資狀況整體相對承壓。但維亞生物作為全球一站式藥物研發生產平台，整體上仍然 取得了不俗的經營成果。在集團融資方面，維亞成功引入了戰略投資人淡馬錫、弘暉、淡明 及 迪 拜 投 資 公 司，完 成 了 累 計 近2.25億美金的融資。在CRO業 務 方 面，公 司 持 續 加 強 生 物 化 學的協同效應並推動BD團 隊 的 建 設，同 時 不 斷 擴 建 新 興 技 術 平 台，以 推 動 藥 物 研 發 平 台 的 完 善 性 建 設。在CDMO業 ...

用簡體 | --- | |--------------------------------------------| | | | 中國法定貨幣人民幣 | | 分別為美利堅合眾國的法定貨幣美元及美分 | | 美利堅合眾國 | | 本公司股本中每股面值 0.000025 美元的普通股 | | | | 香港聯合交易所有限公司 | 指 Viva Biotech Investment Management Limited，為本公 單位計劃 用於計算每股基本及攤薄虧損的母公司權益持有人 9. 股 息 – 40 – 維亞生物科技控股集團 李 向 榮_榮 字 用簡體 | --- | --- | --- | |----------------------------|-------------------------|-----------------------| | | | | | | 二零二三年 | 二零二二年 | | | 人民幣千元 | 人民幣千元 | | 物業、廠房及設備的預付款項 | 6,407 | 27,037 | | 租賃按金 | 850 | 565 | | | 7,257 | 27,602 | | 貿易應收款 ...

智通财经APP讯，维亚生物(01873)公布，公司建议采纳维亚上海第一期股权激励计划及维亚上海第二期股权激励计划，其将使维亚上海能够激励其僱员及董事。 董事会建议，待采纳各自的股权激励计划及取得维亚上海的股东批准后，向若干激励对象授出732万份第一期股票期权及732万份第二期股票期权。 ...

CPIVA 维亚生物科技控股集团 VIVA BIOTECH HOLDINGS (於開曼群島註冊成立的獲豁免有限公司) 股票代號:1873 2023 中期報告 目錄 2 公司資料 4 管理層討論及分析 16 補充資料 40 獨立審閱報告 42 中期簡明綜合損益表 43 中期簡明綜合全面收益表 44 中期簡明綜合財務狀況表 46 中期簡明綜合權益變動表 48 中期簡明綜合現金流量表 50 中期簡明綜合財務資料附註 92 釋 義 1 維亞生物科技控股集團 公司資料 董事會 執行董事 毛晨先生（董事會主席） 吳鷹先生 任德林先生 非執行董事 吳宇挺先生 獨立非執行董事 傅磊先生 李 向 榮 女 士 王海光先生 審核委員會 李 向 榮 女 士（主席） 王海光先生 傅磊先生 薪酬委員會 李 向 榮 女 士（主席） 王海光先生 傅磊先生 提名委員會 毛晨先生（主席） 王海光先生 傅磊先生 聯席公司秘書 費曉玉女士 周慶齡女 士（英國特許公司治理公會 （Chartered Governance Institute）（前 稱 英 國 特 許 秘 書 及 行 政 人 員 公 會）及 香 港 公 司 治 理 公 會（前 稱 香 港 ...

編製中期簡明綜合財務資料所採用的會計政策與編製本集團截至二零二二年十二月三十一日 止 年 度 的 年 度 綜 合 財 務 報 表 所 應 用 者 貫 徹 一 致，惟 於 本 期 間 的 財 務 資 料 首 次 採 納 的 下 列 經 修 訂 國 際 財 務 報 告 準 則（「國際財務報告準則」）除 外。 | --- | --- | |-------------------------------------------------------------|-------------------------------------------------------------------------| | | | | 國際財務報告準則第 17 號 | 保險合約 | | 國際財務報告準則第 17 號修訂本 | 保險合約 | | 國際財務報告準則第 17 號修訂本 | 初步應用國際財務報告準則第 17 號 及 國際財務報告準則第 9 號－比較資料 | | 國際會計準則第 1 號及國際財務報告準則 實務報告第 2 號修訂本 | 會計政策的披露 | | 國際會計準則第 8 號修訂本 | 會計估計的定義 | | 國際會 ...

Financial Performance - For the fiscal year 2022, the total revenue increased to RMB 2,379.6 million, representing a growth of approximately 13.1% compared to RMB 2,104.1 million in the previous year[17]. - The gross profit rose to RMB 815.7 million, reflecting a year-on-year increase of about 25.3% from RMB 651.0 million[17]. - The adjusted net loss under non-IFRS was RMB 133.9 million, a decline from the adjusted net profit of RMB 321.1 million in the previous year, primarily due to market volatility affecting the fair value of investments[17]. - The company reported a net loss of RMB 504.2 million for the year, compared to a profit of RMB 300.6 million in the previous year[9]. - The total contract value of orders on hand reached RMB 1,050.0 million, representing an 8.8% year-on-year increase from RMB 965.0 million[19]. - The company's revenue for the reporting period was approximately RMB 2,379.6 million, an increase of 13.1% from RMB 2,104.1 million in the same period last year[38]. - Gross profit for the reporting period was approximately RMB 815.7 million, up 25.3% from RMB 651.0 million in the previous year[39]. - The net loss for the reporting period was approximately RMB 504.2 million, compared to a net profit of RMB 300.6 million in the same period of 2021[40]. - The adjusted net loss under non-IFRS was approximately RMB 133.9 million, while the adjusted net profit for the same period in 2021 was RMB 321.1 million[40]. - The group recorded a loss of approximately RMB 364.2 million from financial assets measured at fair value, primarily reflecting a decrease in fair value of equity in four incubated investment companies[79]. - Financial costs for the reporting period amounted to approximately RMB 184.7 million, an increase of 0.9% compared to RMB 183.1 million for the year ended December 31, 2021[81]. - The group's net loss for the reporting period was approximately RMB 504.2 million, compared to a net profit of approximately RMB 300.6 million for the year ended December 31, 2021[82]. - Other income and gains decreased by 45.2% to approximately RMB 67.6 million from RMB 123.4 million in the same period last year, primarily due to foreign exchange losses and losses from derivative financial instruments[101]. - The group's income tax expense for the reporting period was approximately RMB 45.1 million, a decrease of 4.2% from approximately RMB 47.1 million for the year ended December 31, 2021[134]. - The group's debt-to-asset ratio was approximately 54.5% as of December 31, 2022, compared to 51.4% as of December 31, 2021, indicating an increase in leverage[137]. - Capital expenditures for the reporting period were approximately RMB 349.8 million, primarily for facility construction and equipment procurement, down from approximately RMB 1,059.0 million for the year ended December 31, 2021[139]. Client and Market Engagement - The number of clients served increased to 2,076 during the reporting period[17]. - The company delivered over 48,925 protein structures cumulatively, with approximately 14,534 new deliveries in 2022, maintaining its leading position in the protein structure analysis field[53]. - The CRO business saw a revenue growth of approximately 23.2% from overseas clients, accounting for about 85.4% of total revenue, while revenue from mainland China clients grew by 9.0%[53]. - As of December 31, 2022, Langhua Pharmaceutical served 852 customers, with the top ten customers accounting for 56.0% of revenue, maintaining a 100% retention rate[52]. - As of December 31, 2022, revenue from the top five customers accounted for 30.0% of total revenue, with the largest customer contributing 18.1%[186]. Research and Development - The company continues to focus on innovative drug development through its CRO and CDMO services, integrating resources to provide comprehensive services from early-stage drug development to commercialization[16]. - The number of ongoing research pipelines in the investment incubation business increased to 215, with 36 pipelines entering the clinical stage[27]. - The company has completed or is progressing on nearly 123 new drug projects since the establishment of the CMC[28]. - The CMC R&D center, covering approximately 10,000 square meters, has been fully operational and includes a 3,000 square meter GMP standard preparation workshop[28]. - The company has constructed multiple core technology platforms, including PROTAC technology platform and various drug screening technologies, contributing to future growth in CRO business[90]. - Research and development investment for the reporting period was RMB 135.8 million, representing a growth of 47.0% compared to RMB 92.4 million for the year ended December 31, 2021[89]. - Research and development expenses increased by 47.0% to approximately RMB 135.8 million from RMB 92.4 million for the year ended December 31, 2021, due to increased investment in internal platform research[104]. Strategic Investments and Growth - The company made strategic investments in several therapeutic firms, including GT Apeiron Therapeutics and Domain Therapeutics, to enhance its drug development capabilities[10]. - The company aims to strengthen its BD team's capabilities to drive order growth and implement a biochemistry integration strategy[19]. - The company is actively applying for a fund manager license in China to establish an investment fund for its incubation business[27]. - The company has incubated 10 companies that have completed or are nearing completion of new financing rounds, totaling approximately USD 158.0 million[64]. - The company aims to enhance its chemical business competitiveness by leveraging biochemical synergies and securing large orders from major pharmaceutical companies[53]. Operational Challenges and Risks - The company faced short-term COVID-19 outbreaks in its R&D and office locations in Shanghai, Jiaxing, and Chengdu, implementing measures to ensure employee safety and project continuity[12]. - There are risks associated with the high failure rate of incubated investment companies engaged in new drug development, which may impact expected investment returns[152]. - The company acknowledges the risk of underperformance in incubation investments, which may lead to significant uncertainty in the fair value of investments[177]. - The company faces foreign exchange risk, having recorded net foreign exchange losses of approximately RMB 146.4 million during the reporting period, compared to net gains of RMB 31.4 million for the year ended December 31, 2021[115]. - Future business may be adversely affected if industry growth trends slow down or if outsourcing ratios decrease[150]. Infrastructure and Capacity Expansion - The company completed the construction of its new headquarters in Shanghai, covering an area of approximately 40,000 square meters, which became fully operational by November 10, 2022[11]. - The company plans to build an additional 400 cubic meters of production capacity by 2024, with ground construction already initiated[52]. - The total available capacity for CDMO has reached 860 cubic meters, with plans to add 400 cubic meters of new capacity in 2024[58]. - The company has accelerated the construction of office and laboratory facilities to meet the demands of rapid business growth, including a 64,564 square meter facility in Chengdu[91]. Compliance and Governance - The company is committed to ensuring compliance with relevant laws and regulations, which may require obtaining permits from government agencies[156]. - The company’s operations must comply with extensive environmental and health and safety regulations, which could impose liabilities regardless of negligence[155]. - The group has no significant violations of applicable laws and regulations as of December 31, 2022[132]. - The company has not faced any significant disputes with clients or suppliers during the reporting period, maintaining good relationships and providing quality services[163]. Employee and Talent Management - The company has expanded its workforce to 2,601 employees, with 1,617 in CRO R&D roles, ensuring competitive compensation to retain talent[91]. - The company is focused on attracting and retaining skilled scientists and management personnel to maintain its technological leadership and service stability[149]. - The company’s ability to maintain competitive compensation levels is crucial to prevent the loss of core technical personnel and management[149]. Financial Instruments and Securities - The company issued $180 million 2.50% guaranteed convertible bonds due in February 2025, with an initial conversion price of HKD 5.7456, representing a 26.0% premium over the closing price on January 22, 2020[168]. - The net proceeds from the issuance of the convertible bonds, after deducting transaction costs of $2.6 million, amounted to $177.4 million[168]. - The company has issued $280 million convertible bonds due in December 2025[169]. - The company has issued a total of 194,118,050 shares upon conversion of the February 2025 convertible bonds, with an additional 10,038,587 shares potentially issuable at the reset conversion price of HKD 5.11[168]. - As of December 31, 2022, the group did not issue any debt securities[200]. - The company maintains the public float required by listing rules as of the report date[197].

Financial Performance - The company's revenue for the year ended December 31, 2022, was RMB 2,379.6 million, representing a 13.1% increase from RMB 2,104.1 million in 2021[4] - Gross profit for the same period was RMB 815.7 million, up 25.3% from RMB 651.0 million in the previous year, with a gross margin of 34.3% compared to 30.9% in 2021[4] - The company reported a net loss of RMB 504.2 million for 2022, compared to a profit of RMB 300.6 million in 2021[4] - Adjusted net loss under non-IFRS was RMB 133.9 million, down from a profit of RMB 321.1 million in the previous year[4] - The total liabilities related to the convertible bonds were allocated between the debt and equity portions, with a difference of USD 3,556,000 recognized in profit or loss[39] - The company reported a total order backlog of approximately RMB 1,050.0 million, representing an 8.8% increase compared to RMB 965.0 million in the same period last year[102] Cash and Liquidity - As of December 31, 2022, cash and cash equivalents amounted to RMB 678,569,000, a decrease of 15.3% from RMB 800,947,000 in 2021[34] - The company repurchased convertible bonds with a total consideration of USD 19,200,000, equivalent to RMB 126,751,000, for a principal amount of USD 30,000,000[39] - The company has sufficient buffer space according to assessments, with no impairment losses recognized for cash-generating units as of December 31, 2022[6] - The company has a discount rate of 15% for cash flow forecasts, with a projected growth rate of 2.5% beyond the five-year period[15] Investments and Assets - The fair value of listed equity securities decreased to RMB 1,407 thousand in 2022 from RMB 5,028 thousand in 2021[11] - The fair value of unlisted investments was RMB 1,045,209 thousand in 2022, down from RMB 1,241,702 thousand in the previous year[11] - The net book value of intangible assets decreased to RMB 476,061 thousand in 2022 from RMB 531,444 thousand in 2021, a decline of 10.4%[90] - The fair value of financial assets at fair value through profit or loss decreased to RMB 1,046,616 thousand by the end of 2022, down from RMB 1,246,730 thousand at the beginning of 2022, a drop of 16%[96] Trade Receivables and Credit Risk - Trade receivables from third parties increased to RMB 447,610 thousand in 2022 from RMB 432,462 thousand in 2021, representing a growth of 3%[80] - The provision for impairment losses on trade receivables rose to RMB 15,124 thousand in 2022, up from RMB 9,452 thousand in 2021, indicating a significant increase of 59%[84] - The aging analysis of trade receivables shows that amounts overdue by more than 1 year increased to RMB 5,962 thousand in 2022 from RMB 3,086 thousand in 2021, reflecting an increase of 93%[81] - The expected credit loss rate for trade receivables was 2.20% overall in 2022, with specific rates of 2.10% for receivables under 6 months, 4.30% for 7 to 12 months, and 10.20% for over 12 months[85] Research and Development - Research and development investment for the year reached RMB 135.8 million, a 47.0% increase from RMB 92.4 million as of December 31, 2021[114] - The company has incubated a total of 91 startups, with 10 of them completing or nearing completion of new financing rounds, totaling approximately USD 158.0 million[113] - The CRO business has established multiple core technology platforms, including PROTAC technology, with PROTAC-related services accounting for nearly 10.2% of total CRO revenue[115] - The company has completed or is advancing nearly 123 new drug projects within its CMC research center, which has a total of 155 research personnel[112] Operational Highlights - The company has maintained a customer retention rate of 100% among its top ten clients, who contribute 56.0% of total revenue[111] - The company aims to strengthen its BD team's capabilities to drive order growth and enhance its strategic integration in biochemistry[102] - The company is leveraging advanced technologies such as Micro ED and AI-assisted drug design to accelerate drug discovery processes[135][136] - The group recorded a net loss during the reporting period, with specific figures not disclosed in the provided content[193] Expenses and Financial Costs - Sales cost for the reporting period was approximately RMB 1,564.0 million, an increase of 7.6% compared to RMB 1,453.1 million for the year ended December 31, 2021, aligning with business growth[167] - Administrative expenses were approximately RMB 273.6 million, a 20.9% increase from RMB 226.3 million for the year ended December 31, 2021, reflecting a rapid increase in personnel[168] - The group recorded other expenses of approximately RMB 254.0 million during the reporting period, compared to RMB 12.7 million for the year ended December 31, 2021, primarily due to increased foreign exchange losses, derivative financial instrument losses, and losses from the repurchase of convertible bonds[190] Future Plans and Strategies - The company plans to redeem all outstanding convertible bonds at 108.21% of the principal amount on February 11, 2025[31] - The company plans to establish investment funds to alleviate cash flow pressure related to its EFS incubation business[133] - The group intends to allocate 10% of the proceeds to recruit, train, and retain personnel in biopharmaceutical research and development, amounting to RMB 121.71 million[189] - The group aims to expand its CMO business with an allocation of 10% of the proceeds, totaling RMB 121.71 million[189]

C, PIVA | --- | --- | --- | |-----------------------------------------------------------------------------------------------|------------------|-------| | | | | | 维亚生物科技控股集团 VIVA BIOTECH HOLDINGS (於開曼群島註冊成立的獲豁免有限公司) 股票代號:1873 | | | | c 是如 ( | | | | 0 | | | | 0 | 2022中期報告 | | 目錄 | --- | --- | |-------|--------------------------| | | | | 2 | 公司資料 | | 4 | 管理層討論及分析 | | 16 | 補充資料 | | 38 | 獨立審閱報告 | | 39 | 中期簡明綜合損益表 | | 40 | 中期簡明綜合全面收益表 | | 41 | 中期簡明綜合財務狀況表 | | 43 | 中期簡明綜合權益變動表 | | 45 | 中期簡明綜合現金流量表 | | 47 | 中期簡明綜合 ...

CXIVA 维亚生物科技控股集团 VIVA BIOTECH HOLDINGS (於開曼群島註冊成立的獲豁免有限公司) 股票代號:1873 2021 年度報告 目錄 | --- | --- | |-------|------------------| | | | | 2 | 公司資料 | | 4 | 主席致辭 | | 6 | 財務概要及摘要 | | 9 | 管理層討論及分析 | | 22 | 董事會報告 | | 38 | 董事及高級管理層 | | 45 | 企業管治報告 | | 60 | 其他資料 | | 78 | 獨立核數師報告 | | 84 | 綜合損益表 | | 85 | 綜合全面收益表 | | 86 | 綜合財務狀況表 | | 89 | 綜合權益變動表 | | 91 | 綜合現金流量表 | | 95 | 綜合財務報表附註 | | 227 | 釋 義 | * 我們將另行刊發截至二零二一年十二月三十一日止年度的環境、社會及管治報告（「環境、社會及管治報告」）， 以向社區、公眾股東及所有相關方匯報更多我們於二零二 一 年的環境、社會及管治實踐。環境、社會及管治 報告將於 財政年度後五個月內 刊載於聯交所及本公 ...